Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
47,000
Employees47,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
47,000
Employees47,000

LLY Key Statistics

Market cap
996.15B
Market cap996.15B
Price-Earnings ratio
44.23
Price-Earnings ratio44.23
Dividend yield
0.59%
Dividend yield0.59%
Average volume
4.31M
Average volume4.31M
High today
$1,053.97
High today$1,053.97
Low today
$1,012.00
Low today$1,012.00
Open price
$1,024.63
Open price$1,024.63
Volume
2.03M
Volume2.03M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 996.15B, Eli Lilly(LLY) trades at $1,053.70. The stock has a price-to-earnings ratio of 44.23 and currently yields dividends of 59.1%.

On 2026-02-12, Eli Lilly(LLY) stock moved within a range of $1,012.00 to $1,053.97. With shares now at $1,053.70, the stock is trading +4.1% above its intraday low and -0.0% below the session's peak.

Trading volume for Eli Lilly(LLY) stock has reached 2.03M, versus its average volume of 4.31M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

LLY News

TipRanks 4h
Eli Lilly Stock Gets New ‘Buy Rating’ After Strong Earnings

Eli Lilly’s stock (LLY) has received a new Buy rating following recent financial results that blew past Wall Street forecasts. Ilya Zubkov, an analyst at Freed...

Zacks 5h
The Zacks Analyst Blog Highlights Eli Lilly, Marriott International, Fortinet, GSI Technology and Kewaunee Scientific

This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herei...

The Zacks Analyst Blog Highlights Eli Lilly, Marriott International, Fortinet, GSI Technology and Kewaunee Scientific
Nasdaq 10h
Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know.

Key Points Eli Lilly and Novo Nordisk dominate the weight loss drug market, one that soon may approach $100 billion. One of these players has recently gained...

Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know.

Analyst ratings

78%

of 32 ratings
Buy
78.1%
Hold
18.8%
Sell
3.1%

More LLY News

Simply Wall St 20h
A Look At Eli Lilly’s Valuation After Recent Share Price Pullback

Advertisement What Eli Lilly’s Recent Share Performance Signals for Investors Eli Lilly (LLY) has recently seen its share price under pressure, with a 1 day r...

A Look At Eli Lilly’s Valuation After Recent Share Price Pullback
The Motley Fool 1d
Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.

Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks. There are...

Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.
TipRanks 2d
Fisher Asset Management Boosts Eli Lilly Stake by 153K Shares

Fisher Asset Management LLC, managed by Ken Fisher, recently executed a significant transaction involving Eli Lilly And Company ((LLY)). The hedge fund increase...

Nasdaq 2d
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Key Points Eli Lilly set the bar high, and it will be hard for other drugmakers to match its performance. Viking Therapeutics and Abivax are developing promis...

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Simply Wall St 2d
Eli Lilly Expands Genetic Medicines Pipeline And Valuation Case With New Deals

Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics, adding circular RNA and lipid nanoparticle platforms for in vivo cell therapies targeting autoimmune d...

Eli Lilly Expands Genetic Medicines Pipeline And Valuation Case With New Deals
TipRanks 2d
Eli Lilly upgraded to Buy from Hold at Freedom Capital

Freedom Capital analyst Ilya Zubkov upgraded Eli Lilly (LLY) to Buy from Hold with a price target of $1,200, up from $1,050, following what the firm describes a...

TipRanks 2d
Lilly Advances Eloralintide Into Phase 3, Expanding Its Obesity Drug Ambitions

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The Phase 3 study “A Study of Eloralintide (LY3841136) in Participants With Pe...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.